OncoMatch/Clinical Trials/NCT04722692
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Is NCT04722692 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for dcis.
The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessary and should be avoided. This includes but is not limited to patients with a preoperative diagnosis of ductal cancer in situ of the breast (DCIS), an unclear BIRADS 4-5 planned for diagnostic excision or women planned for risk reducing mastectomy. SPIO is injected in the primary operation, and should final specimen pathology demonstrate invasive breast cancer, only then is an operation in the axilla (d-SLND) performed.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Baylor College Of Medicine · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify